Genzyme Recalls Murky Batches Of Transplant Drug

Law360, New York (April 11, 2008, 12:00 AM EDT) -- Genzyme Corp. has voluntarily recalled 100,000 vials of Thymoglobulin, a drug widely used during kidney transplants, even though most of the batches have already been used without any complaints or adverse reactions.

The company recalled the batches after federal regulators noticed vials of the drug appeared cloudier than normal during a routine quality control inspection, a spokeswoman for Genzyme said Friday.

The three recalled lots of the drug, manufactured in 2007, do not pose a health risk to patients and the company does not expect to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.